Piotr Swat | Lightrocket | Getty Photos
As its high-margin compounded GLP-1 enterprise evolves, Hims & Hers Well being could also be discovering a brand new alternative in peptides.
Shares of the telehealth firm jumped Thursday after Well being and Human Providers Secretary Robert F. Kennedy Jr. introduced Wednesday that the FDA plans to convene a Pharmacy Compounding Advisory Committee assembly to evaluate peptides for potential inclusion on the 503A bulk record, a designation that permits medication to be compounded on a person prescribed foundation fairly than mass producing.
For Hims, the larger story is how increasing compounding for peptides may unlock new income streams because it directs members towards branded fairly than extra worthwhile compounded GLP-1 medication. The telehealth firm has been constructing towards a peptide enterprise for years.
Peptides are brief chains of amino acids — consider them as small constructing blocks of proteins — which are being explored for a variety of well being and wellness makes use of. They’re controversial as a result of scientific proof on their long-term security and effectiveness is restricted, and their manufacturing stays largely unregulated.
Hims & Hers made a big transfer into the area in February 2025 when it acquired a California-based peptide facility. On the time, CEO Andrew Dudum referred to as peptide demand “future-facing innovation.”
“Many use circumstances have but to be launched,” mentioned Dudum. “Peptide innovation is on the forefront of so many classes we’re excited to begin providing.”
Following Kennedy’s announcement on Wednesday, Hims Chief Medical Officer Dr. Patrick Carroll applauded the information as a transfer away from the “grey market,” saying the aim is to carry peptide remedy into regulated, physician-led care.
“Our medical workforce believes sure peptide therapies maintain significant potential in serving to People dwell more healthy lives, and we’re actively exploring learn how to increase entry in a means that shall be aligned with FDA steering,” Carroll mentioned.
Leerink Companions referred to as the information that the FDA will evaluate peptides for the compounding record a constructive consequence that might give Hims a clearer regulatory path to scale peptide therapies. Even so, the agency mentioned it would take time for peptides to spice up the corporate’s backside line.
“This could not instantly translate into income, however would seemingly be a development avenue that HIMS would push laborious on,” mentioned Leerink analyst Michael Cherny, who has a hold-equivalent score on the inventory and a $25 value goal. The inventory was buying and selling at round $26 a share Thursday.
For now the chance continues to be early, and scientific proof supporting many peptide therapies continues to be restricted.
Of the dozen peptides listed by Kennedy for consideration on the compounding bulk record, one — MK-677 — is commonly handled as an unlawful drug when offered for human consumption. The expansion hormone has additionally been banned by the World Anti-Doping Company.
Different peptides on the record, comparable to GHK-Cu and Semax, that are used for beauty or cognitive enhancement, are usually seen as much less controversial, however nonetheless lack strong scientific backing.
Kennedy — who has supported many medical therapies and meals choices outdoors of these backed by mainstream science — was requested about his plans for increasing peptide therapies throughout a Home Methods and Means Committee listening to Thursday.
“Peptides weren’t alleged to be regulated,” Kennedy mentioned, arguing the Biden administration restricted using peptides resulting from security issues that he considers unfounded.
The FDA course of is simply starting, and the July assembly shall be advisory solely, so change is just not anticipated to be speedy.
Even so, traders are already specializing in what replaces GLP-1 as a development driver for Hims, and peptides are rising as one of many clearest candidates to date.
